Actively Recruiting
MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
Led by Medical College of Wisconsin · Updated on 2026-05-13
40
Participants Needed
1
Research Sites
469 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a single arm pilot study for patients with hematologic malignancies receiving unrelated or haploidentical related mobilized peripheral stem cells (PSCs) using the CliniMACS system for alpha/beta T cell depletion plus CD19+ B cell depletion with individualized ALC-based dosing of ATG to study impact on engraftment, GVHD, and disease free survival
CONDITIONS
Official Title
MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient is younger than 25 years old
- Diagnosed with one of the following diseases in remission or specified status: acute myeloid leukemia (MRD negative), myelodysplasia, acute lymphoblastic leukemia (MRD negative), chronic myelogenous leukemia (chronic phase, accelerated phase, or blast crisis now in second chronic phase), mixed lineage or biphenotypic acute leukemia (MRD negative), lymphoblastic lymphoma (in remission), Burkitt's lymphoma/leukemia (in remission), lymphoma after relapse (in remission), or other malignant hematologic diseases approved by the principal investigator
- Karnofsky Performance Status of 60% or higher for patients 16 years and older, or Lansky Play Score of 60 or higher for patients under 16 years
- Organ function evaluated as per study procedures
- No active untreated infection; fungal infections must be treated for at least 2 weeks and asymptomatic
- Signed consent from parent/guardian or patient if 18 years or older
- Negative pregnancy test for patients capable of childbearing
- Sexually active patients capable of childbearing must agree to use effective contraception during treatment; sexually active men must use barrier contraception during treatment
- Donor meets National Marrow Donor Program criteria and is willing to undergo G-CSF mobilization and peripheral blood stem cell collection
- Unrelated donors must be matched at 9/10 or 10/10 HLA alleles; haploidentical related donors must be at least 5/10 HLA allele match
You will not qualify if you...
- Patients who do not meet disease, organ function, or infection criteria
- No suitable donor available
- Pregnant or breastfeeding patients
- Receiving other chemotherapy, radiation, immunotherapy, or anti-cancer treatments not specified in the protocol
- Participating in other Phase 1 or 2 treatment studies for the disease
- Active malignancy other than the eligible diseases specified; prior malignancies allowed if at least 1 year post-treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Children's Wisconsin
Milwaukee, Wisconsin, United States, 53226
Actively Recruiting
Research Team
M
Meredith Beversdorf, RN
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here